Synopsis
I. GENERAL CONCEPTS
1. Epidemiology and natural history
Edward Messing and Emil Scosyrev
2. Screening for Bladder Cancer
Laura-Maria Krabbe, Robert S. Svatek and Yair Lotan
3. Pathology and Staging: Histopathology and Cytopathology
Amber Mackey, Farnaz Hasteh and Donna E. Hansel
4. Pathology and Staging: Genetics and Molecular Biology
Sean McAdams and Michael C. Risk
5. Imaging in Localized and Advanced Bladder Cancer
Timothy Kim, Joshua G. Griffin, Jeffrey M. Holzbeierlein and Wade J. Sexton
6. New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder
Ramdev Konijeti and Adam S. Kibel
7. Socioeconomic issues and improved quality of care
John L. Gore
8. Quality of life measures
Christopher B. Anderson, David F. Penson and Daniel A. Barocas
9. Prognostication and risk assessment
Luis Alex Kluth, Bernie Bochner and Shahrokh F. Shariat
10. Clinical trials and emerging therapeutic strategies in bladder cancer
Richard M. Bambury, Robert B. Sims and Jonathan E. Rosenberg
II. NON MUSCLE INVASIVE BLADDER CANCER
11. Improved diagnostic techniques
Seth P. Lerner and Alvin C. Goh
12. Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging
Christopher S. Gomez, Mark S. Soloway, Jorge Caso, Claudia P. Rojas and Merce Jorda
13. Localized surgical therapy and surveillance
Manish I. Patel and Paul D. Sved
14. Clinical Scenario: Initial high grade Ta tumor
Jose L. Dominguez-Escrig and Eduardo Solsona Narbón
15. Clinical Scenario: Recurrent Ta tumor
Joseph A. Gillespie and Michael A. O'Donnell
16. Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor
James S. Rosoff and Thomas A. Keane
17. Clinical Scenario: Low grade T1 tumor
J. Alfred Witjes and Florine W.M. Schlatmann
18. Intravesical therapy
Jennifer J. Ahn and James M. McKiernan
19. Clinical Scenario: Initial CIS
Sima P. Porten and Colin P. Dinney
20. Management of BCG Recurrent Bladder Cancer
Tracy M. Downs, Daniel J. Lee and Douglass S. Scherr
21. Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG
Maurizio Brausi
22. Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation
Donald L. Lamm and Nilay M. Gandhi
23. Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines
Jeffrey C. Bassett, John D. Seigne and Peter E. Clark
III. MUSCLE INVASIVE BLADDER CANCER
24. Open Radical Cystectomy
J. Joy Lee, Dipen J. Parekh and Mark L. Gonzalgo
25. Robotic cystectomy
Michael Woods, Raj Pruthi and Erik P. Castle
26. Clinical Scenario: T2 bladder tumor
Richard E. Hautmann
27. Urinary Diversion: Open and robotic techniques
Norm D. Smith, Gary D. Steinberg and Cheryl T. Lee
28. Chemoradiotherapy
Christian Weiss and Claus Rödel
29. Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation
Albert J. Chang, Maurice Marcel Garcia and Mack Roach III
30. Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application
Gautam Jha, Guru Sonpavde and Zeeshan Ahmad
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
